[
    [
        {
            "time": "",
            "original_text": "医药行业2020年四季度投资策略：业绩验证化解估值压力",
            "features": {
                "keywords": [
                    "医药行业",
                    "四季度",
                    "投资策略",
                    "业绩验证",
                    "估值压力"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药行业2020年四季度投资策略：业绩验证化解估值压力",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业2020三季度业绩前瞻：板块分化明显 医疗服务等板块有序复苏",
            "features": {
                "keywords": [
                    "医药生物",
                    "三季度",
                    "业绩前瞻",
                    "板块分化",
                    "医疗服务",
                    "复苏"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "医疗服务"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业2020三季度业绩前瞻：板块分化明显 医疗服务等板块有序复苏",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "【健帆生物（300529.SZ）】开源节流多因素共振，20Q3利润环比大幅提速——2020年三季报预告点评（林小伟/宋硕）",
            "features": {
                "keywords": [
                    "健帆生物",
                    "开源节流",
                    "多因素共振",
                    "20Q3",
                    "利润环比提速",
                    "三季报预告"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【健帆生物（300529.SZ）】开源节流多因素共振，20Q3利润环比大幅提速——2020年三季报预告点评（林小伟/宋硕）",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]